The Use of Ribociclib plus Letrozole in Patients with CNS Metastases

Web Exclusives —December 15, 2020

Approximately 10% to 30% of patients with metastatic breast cancer are diagnosed with central nervous system (CNS) metastases, which are associated with a poor prognosis and are a major cause of morbidity and mortality. Due to improving diagnostics and treatments for breast cancer, leading to longer patient survival, more CNS metastases in patients with breast cancer are being detected. However, patients with CNS metastases are often excluded from clinical trials.

Ribociclib (Kisqali), an oral, selective cyclin-dependent kinase 4/6 inhibitor, is approved for use in combination with endocrine therapy in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.

Paul Cottu, MD, MSc, Medical Oncologist, Curie Institute, Paris, France, and colleagues presented a subgroup analysis of patients with CNS metastases at baseline from the Core Phase of CompLEEment-1, a phase 3b clinical trial of ribociclib in combination with letrozole in patients with HR-positive, HER2-negative advanced breast cancer. The eligibility criteria for this study allowed a broader and more diverse patient population than those of previous phase 3 trials of ribociclib plus letrozole, to reflect a typical real-world clinical setting.

The CompLEEment-1 study included women of any menopausal status and men with HR-positive, HER2-negative advanced breast cancer treated with up to 1 line of previous chemotherapy and no previous hormonal therapy for advanced disease. Patients received ribociclib at a dose of 600 mg every day for 3 weeks on then 1 week off, combined with letrozole 2.5 mg daily. Men and premenopausal women received a luteinizing hormone-releasing hormone agonist at a dose of 3.6 mg goserelin or 7.5 mg leuprolide, every 28 days.

This subgroup analysis assessed the primary outcomes of safety and tolerability and secondary outcomes of time to progression, overall response rate, and clinical benefit rate in patients with CNS metastases.

Fifty-one patients with CNS metastases, reflecting 1.57% of the total patient population (N = 3246), were evaluated. The median age was 56.0 years. Approximately 59% of the patients were postmenopausal. An Eastern Cooperative Oncology Group performance status of <2 was observed in 96.1% of patients. Approximately 17 months was the median duration of exposure to ribociclib.

Three-quarters (74.5%) of patients reported grade ≥3 adverse effects. Eight patients reported serious adverse effects, including 1 fatal case of sepsis. Neutropenia was reported in 66.7% of patients, the most common of the all-grade adverse effects, followed by nausea in 39.2% and vomiting in 29.4% of patients. The most common grade ≥3 adverse effect was neutropenia reported by more than half (51.0%) of patients, followed by leukopenia (13.7%).

Overall, 37.3% of patients had ≥1 dose reductions of ribociclib, 23.5% due to side effects, and nearly two-thirds (62.7%) permanently discontinued treatment, of which 11.8% was due to side effects. The overall response rate was 42.9%, and the clinical benefit rate was 62.9%.

The investigators concluded that the use of ribociclib plus letrozole in patients with CNS metastases is supported by the subgroup analysis from CompLEEment-1. These patients typically have poor outcomes and are frequently excluded from clinical trials. Yet in this close to real-world setting, the efficacy results in this study highlight the potential benefit of using ribociclib plus letrozole in HR-positive, HER2-negative advanced breast cancer. With few patients discontinuing treatment due to side effects, the safety profile associated with ribociclib plus letrozole was manageable, and the outcomes were consistent with previous phase 3 trials.

Related Articles
Early Intervention Strategies for Management of Alpelisib-Induced Hyperglycemia
Web Exclusives
Preliminary recommendations made based on cases from the SOLAR-1 trial suggest that alpelisib-induced hyperglycemia can be managed with early detection, close monitoring, and prompt intervention.
Cost Analysis of Neratinib in an Extended Adjuvant Treatment Setting for Patients with Early-Stage, HR-Positive, HER2-Positive Breast Cancer
Web Exclusives
For patients with early HR-positive, HER2-positive breast cancer who initiated neratinib within 1 year of completing trastuzumab and in patients who did not achieve a pathologic complete response after neoadjuvant treatment, neratinib may be a cost-effective treatment option.
Effect of Multiple Certified Educational Activities on Knowledge and Competence with CDK4/6 Inhibitors in HR-Positive Breast Cancer
Web Exclusives
Participation in certified educational activities resulted in significant improvements in knowledge, competence, and confidence regarding the use of CDK4/6 inhibitor therapies in the management of patients with advanced HR-positive breast cancer.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country